Apellis Pharmaceuticals Management
Management criteria checks 2/4
Apellis Pharmaceuticals' CEO is Cedric Francois, appointed in Sep 2009, has a tenure of 15.33 years. total yearly compensation is $10.37M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 1.41% of the company’s shares, worth $53.12M. The average tenure of the management team and the board of directors is 5.9 years and 9.5 years respectively.
Key information
Cedric Francois
Chief executive officer
US$10.4m
Total compensation
| CEO salary percentage | 7.1% |
| CEO tenure | 15.3yrs |
| CEO ownership | 1.4% |
| Management average tenure | 5.9yrs |
| Board average tenure | 9.5yrs |
Recent management updates
Recent updates
Apellis: Saved By The October Data
Dec 25There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise
Dec 15
Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?
Oct 18Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
Oct 01Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues
Sep 27Apellis: Rare Kidney Disease Data Leads To Possible First To Market
Aug 09Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?
Jul 12What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You
May 30It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year
May 30Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
Feb 16With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For
Jul 19Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week
May 13Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?
Apr 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$250m |
| Jun 30 2024 | n/a | n/a | -US$333m |
| Mar 31 2024 | n/a | n/a | -US$417m |
| Dec 31 2023 | US$10m | US$735k | -US$529m |
| Sep 30 2023 | n/a | n/a | -US$606m |
| Jun 30 2023 | n/a | n/a | -US$657m |
| Mar 31 2023 | n/a | n/a | -US$691m |
| Dec 31 2022 | US$9m | US$681k | -US$652m |
| Sep 30 2022 | n/a | n/a | -US$634m |
| Jun 30 2022 | n/a | n/a | -US$638m |
| Mar 31 2022 | n/a | n/a | -US$702m |
| Dec 31 2021 | US$9m | US$647k | -US$746m |
| Sep 30 2021 | n/a | n/a | -US$520m |
| Jun 30 2021 | n/a | n/a | -US$460m |
| Mar 31 2021 | n/a | n/a | -US$360m |
| Dec 31 2020 | US$9m | US$619k | -US$345m |
| Sep 30 2020 | n/a | n/a | -US$536m |
| Jun 30 2020 | n/a | n/a | -US$470m |
| Mar 31 2020 | n/a | n/a | -US$423m |
| Dec 31 2019 | US$4m | US$560k | -US$305m |
| Sep 30 2019 | n/a | n/a | -US$228m |
| Jun 30 2019 | n/a | n/a | -US$194m |
| Mar 31 2019 | n/a | n/a | -US$156m |
| Dec 31 2018 | US$4m | US$550k | -US$128m |
Compensation vs Market: Cedric's total compensation ($USD10.37M) is above average for companies of similar size in the US market ($USD6.64M).
Compensation vs Earnings: Cedric's compensation has increased whilst the company is unprofitable.
CEO
Cedric Francois (52 yo)
15.3yrs
Tenure
US$10,373,049
Compensation
Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.3yrs | US$10.37m | 1.41% $ 53.1m | |
| Co-Founder & Director | 16yrs | US$495.96k | 0.63% $ 23.8m | |
| CFO & Treasurer | 7.3yrs | US$3.74m | 0.099% $ 3.7m | |
| Chief Operating Officer | 1yr | US$3.71m | 0.034% $ 1.3m | |
| General Counsel | 11yrs | US$4.89m | 0.10% $ 3.9m | |
| Chief Medical Officer | 2yrs | US$4.43m | 0.014% $ 511.9k | |
| Co-Founder & Chief Scientific Officer | 15.3yrs | US$3.08m | 0.90% $ 34.0m | |
| VP, Corporate Controller & Chief Accounting Officer | 3.4yrs | no data | 0.014% $ 539.8k | |
| Senior Vice President | no data | no data | no data | |
| Chief People Officer | 4.7yrs | no data | 0.012% $ 465.0k | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 2.7yrs | no data | no data | |
| Senior Vice President | 5.9yrs | no data | no data |
5.9yrs
Average Tenure
51.5yo
Average Age
Experienced Management: APLS's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.3yrs | US$10.37m | 1.41% $ 53.1m | |
| Co-Founder & Director | 15.3yrs | US$495.96k | 0.63% $ 23.8m | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 9.5yrs | no data | no data | |
| Independent Chairman of the Board | 11.5yrs | US$504.08k | 0.014% $ 537.9k | |
| Independent Director | 11.5yrs | US$488.46k | 0.014% $ 537.9k | |
| Member of AMD Scientific Advisory Board | 9.5yrs | no data | no data | |
| Member of PNH Scientific Advisory Board | 9.5yrs | no data | no data | |
| Member of Pulmonology Scientific Advisory Board | 9.5yrs | no data | no data | |
| Independent Director | 4.8yrs | US$489.08k | 0.0046% $ 172.4k | |
| Independent Director | 14.8yrs | US$480.96k | 0.12% $ 4.6m | |
| Member of Pulmonology Scientific Advisory Board | no data | no data | no data | |
| Member of Pulmonology Scientific Advisory Board | 9.5yrs | no data | no data |
9.5yrs
Average Tenure
57.5yo
Average Age
Experienced Board: APLS's board of directors are considered experienced (9.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 05:12 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Apellis Pharmaceuticals, Inc. is covered by 34 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Michael Ulz | Baird |
| Ishan Majumdar | Baptista Research |